Lilly(Eli) (LLY) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Lilly(Eli) (LLY) do?
Lilly(Eli) & Co (LLY) is a U.S.-listed company in Healthcare (Drug Manufacturers - General). What it does: Discovers, manufactures, and sells prescription medicines for diabetes, obesity, cancer, and autoimmune diseases worldwide. Produces metabolic and oncology medicines anchored by massive multi-incretin diabetes and obesity manufacturing. It is worth $1.27T on the market and sold $86.47B over the last year.
- Market cap
- $1.27T
- P/E ratio
- 44.4×
- Annual sales
- $86.47B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Brief updated
- Nov 08, 2026
Brands and businesses behind LLY
- Mounjaro: Injectable dual incretin therapy for type 2 diabetes that earns via prescription sales.
- Zepbound: Injectable chronic weight management medication sold through retail and direct pharmacies.
- Verzenio: Oral targeted therapy for early and metastatic breast cancer sold to oncology providers.
- Trulicity: Weekly injectable diabetes therapy earning revenue from wholesale and retail pharmacies.
- Taltz: Injectable biologic treating plaque psoriasis and arthritis distributed through specialty pharmacies.
- Jardiance: Oral diabetes and heart failure medicine generating shared alliance revenue.
LLY’s flags, in plain English
Each flag is a number from Lilly(Eli)’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 08, 2026.
Fat Margins
Profit margin of 31.9%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.
Wide Gross Margin
Gross margin of 83.6% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Earns Its Keep
Earns 86.1% a year on shareholders' money. The company earns a healthy return on the money its shareholders have put in.
Debt Is Driving
Heavy debt, 123% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about LLY
How big is Lilly(Eli)?
Lilly(Eli)’s market cap is $1.27T: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $86.47B: what customers paid the company over the last year, before any costs.
What is LLY’s P/E ratio?
LLY’s P/E ratio is 44.4×. Investors pay about 44.4 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with LLY?
High capital spending required to build sterile injectables capacity limits free cash flow generation. That is one risk on Lilly(Eli)’s card. Its first risk flag is Debt Is Driving, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Lilly(Eli)’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. LLY’s filings on SEC.gov. The Margin Monkey is research, not advice.
